Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

<p>Persistence of Tcm-derived CD19-CAR T cells</p>

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkki: Ibrahim Aldoss (15055961) (author)
Eará dahkkit: Samer K. Khaled (15055964) (author), Xiuli Wang (15055967) (author), Joycelynne Palmer (15055970) (author), Yan Wang (15055973) (author), Jamie R. Wagner (15055976) (author), Mary C. Clark (15055979) (author), Jennifer Simpson (15055982) (author), Jinny Paul (15055985) (author), Vibhuti Vyas (15055988) (author), Sheng-Hsuan Chien (15055991) (author), Anthony Stein (15055994) (author), Vinod Pullarkat (15047900) (author), Amandeep Salhotra (15055997) (author), Monzr M. Al Malki (15056000) (author), Ahmed Aribi (15056003) (author), Karamjeet Sandhu (15056006) (author), Sandra H. Thomas (15056009) (author), Lihua E. Budde (15056012) (author), Guido Marcucci (11252666) (author), Christine E. Brown (15056015) (author), Stephen J. Forman (15056018) (author)
Almmustuhtton: 2025
Fáttát:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Hematological Cancers
Leukemias
Immunotherapy
Cellular immunotherapy
Engineered/CAR T cells
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid